Brandon Couillard

Jefferies raised its price target on OraSure Technologies, Inc. (NASDAQ: OSUR) from $10 to $12 and maintained a Buy rating. Analyst Brandon Couillard noted that “Nielsen's monthly data for OSUR's OTC HIV test indicates retail unit volume sell-through increased 6 percent...

In a report published Thursday, Jefferies analyst Brandon Couillard resumed coverage on Sequenom (NASDAQ; SQNM) with a Buy rating and $5.00 price target, up from $4.50. In the report, Jefferies noted, “We are resuming our rating on SQNM with a Buy and $5 PT (Restricted 9/23/13). Our revised revenue...

In a report published Thursday, Jefferies analyst Brandon Couillard reiterated a Buy rating on Agilent Technologies (NYSE: A), and raised the price target from $50.00 to $54.00. In the report, Jefferies noted, “A's 3Q13 EPS of $0.68 was $0.06 (+10%) above consensus on stronger core revenue and...

In a report published Friday, Jefferies analyst Brandon Couillard reiterated a Buy rating on EXACT Sciences (NASDAQ: EXAS), and raised the price target from $14.00 to $18.00. In the report, Jefferies noted, “Our proprietary physician survey points to a strong launch for EXAS' novel colorectal...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Luminex (NASDAQ: LMNX) with a Hold rating, and raised the price target from $17.00 to $20.00. In the report, Jefferies noted, “Cautious on long-term profitability goals. LMNX has successfully relied upon...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Genomic Health (NASDAQ: GHDX) with a Hold rating, and raised the price target from $32.00 to $35.00. In the report, Jefferies noted, “We are assuming coverage of GHDX with a Hold rating and $35 price target....

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Sequenom (NASDAQ: SQNM) with a Buy rating, but lowered the price target from $7.50 to $6.00. In the report, Jefferies noted, “SQNM's flagship MaterniT21 test continues to ramp at a blistering clip, formal...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on OraSure Technologies (NASDAQ: OSUR) with a Buy rating, but lowered the price target from $12.00 to $8.00. In the report, Jefferies noted, “Concerns around weaker demand trends in OSUR's legacy product...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Nanosphere (NASDAQ: NSPH) with a Buy rating, and raised the price target from $3.50 to $5.50. In the report, Jefferies noted, “Aided by its first mover-advantage status, we expect NSPH's proprietary gram-...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on EXACT Sciences (NASDAQ: EXAS) with a Buy rating, and raised the price target from $12.00 to $14.00. In the report, Jefferies noted, “We are assuming coverage of EXAS at Buy and raising our price target to $14...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Myriad Genetics (NASDAQ: MYGN), downgraded the rating from Buy to Hold, but reiterated the $31.00 price target. In the report, Jefferies noted, “MYGN continues to present an attractive organic revenue growth...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Cepheid (NASDAQ: CPHD), downgraded the rating from Buy to Hold, but reiterated the $38.00 price target. In the report, Jefferies noted, “CPHD is well-positioned to realize significant margin expansion over the...

In a report published on Friday, Jefferies analyst Brandon Couillard downgraded Cepheid (NASDAQ: CPHD) from Buy to Hold and maintained a price target of $38.00. In the report, Jefferies noted, "CPHD has placed >1,000 systems in HBDC (high burden & developing countries) markets, which...

In a report published Tuesday, Jefferies analyst Brandon Couillard downgraded the rating on Align Technology (NASDAQ: ALGN) from Buy to Hold, but raised the price target from $36.00 to $38.00. In the report, Jefferies noted, “We are lowering our rating on ALGN to Hold (from Buy). Our 2013 /...